Biotech news
Americas
German biotech asks federal judge to reject Amgen’s efforts to narrow scope of a key patent in ongoing dispute | Patent relates to Lindis' cancer immunotherapy treatment | Lindis calls on court to uphold the broader interpretation and claims Amgen’s attempt to narrow is inconsistent with the patent's history. 3 December 2024
Americas
New England Biolab contends plaintiff’s patents are invalid and cover “unpatentable natural processes”| Biomodal had accused rival of infringing several patents covering methods to detect and modify DNA methylatian—a key part of epigenetic research 28 November 2024
Americas
Key similarities and differences between the patent systems, particularly in biotech, offer lessons and opportunities for rightsholders, say Daniela Fasoli of Simões Propriedade Intelectual and Jeffrey Morton of Haynes and Boone. 28 November 2024
Europe
European panel deals blow to a biotech company over human milk oligosaccharides used in infant formula | Patent opposed by giant Nestlé, FrieslandCampina, and Danisco questioning its inventive step. 26 November 2024
Americas
Judges at Munich Local Division determined that Meril infringed Edwards Lifesciences’ patent | Meril ordered to stop selling and recall product as well as pay damages. 19 November 2024
Americas
Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight. 14 November 2024
Careers
Sapna Palla joins the firm in New York, bringing significant experience in complex life sciences and IP disputes to a growing practice. 12 November 2024
Asia
Free trade zones in Beijing, Shanghai, Guangdong, and Hainan are designed to attract capital into China’s fast-growing healthcare sectors, says Li Mi of Lusheng. 7 November 2024
Americas
Well-drafted contracts and ironclad tech security can save time and money when an ex-employee steals IP ‘like sugar packets in Starbucks’, finds Tom Phillips. 7 November 2024
Americas
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages. 5 November 2024